Business
GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Presented novel TriKE® pre-clinical data driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment
About this update from Gt Biopharma, Inc.
[{"type":"text","content":"Presented novel TriKE® pre-clinical data driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor microenvironment at ESMO TAT Congress.Demonstrated novel B7-H3 targeting dual camelid nanobody TriKE® and GTB-5550 induce NK cell activation against broad spectrum of tumors at ESMO IO Congress 2021.GT Biopharma to participate in poster-presentation sessions at the following upcoming EBMT and AACR medical conferences.$32.0 million in cash, cash equivalents and short-term investments as of December 31, 2021, is expected to provide ample runway to fund operations into 2023, including Phase 1 clinical development of its lead products GTB-3650 and GTB-5550.BRISBANE, Calif., March 28, 2022 /PRNewswire/ -- GT Biopharma, Inc. (the \"Company\") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced fourth quarter and full-year 2021 results for the period ended December 31, 2021.\n\n \n \n \n \n \n \n\n \n\"We're excited for GTB-3650's prospects in the new year as we advance the Company's second-generation Tri-specific NK cell engager (TriKE®) technology into an IND-enabling study. The development of GTB-3650, our lead-asset second generation nanobody TriKE® has been significantly de-risked, propelled by GTB-3550 predecessor data published in 2021 including: positive first-in-human Phase 1 data; and in-vivo animal model data, conducted in combination with a bispecific killer cell engager asset,\" said Michael Breen, Executive Chairman and Interim Chief Executive Officer. \"Our optimism continues to rise as these proof-of-concept data demonstrate a well-tolerated safety profile and strong NK cell activation against a broad range of tumors. In total, the Company's TriKE® nanobody platform, a rich platform technology, has demonstrated broad utility. We are confident in our ability to develop these assets as a monotherapy, as a combination therapy with conventional chemotherapy, or in combination with other potential joint commercialization technologies.\"\nQuarterly HighlightsThe Company presented pre-clinical TriKE® data in an oral poster-presentation both virtually and in-person at ESMO Targeted Anticancer Therapies (TAT) Congress, March 7–8, 2022.The p...